Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million Achieved record quarterly revenue of $25 million and annual revenue of $85.9 million New credit facilities’ favorable interest rates and amortization schedules free up approximately $19 million in cash in 2025 In-licensed two new […]
Theratechnologies Inc. reported record financial results for the fourth quarter and full year of fiscal 2024, achieving quarterly revenue of $25 million and annual revenue of $85.9 million. The company also achieved a record positive Adjusted EBITDA of $20 million, surpassing its previous guidance. Key highlights include the closure of $75 million in new credit facilities to support growth, the in-licensing of two Ionis assets for long-term growth, and the temporary supply disruption of EGRIFTA SV® caused by an FDA inspection, which has since resumed manufacturing. The company also received a PDUFA action date of March 25, 2025, for its updated tesamorelin F8 formulation.
